Acutus Medical (AFIB) Q3 2024 earnings summary

Executive summary

• Shifted business model to focus solely on manufacturing and distributing Medtronic's left-heart access products, winding down mapping and ablation businesses as of Q1 2024.

• Revenue now generated exclusively from Medtronic partnership, including product sales and earnout payments.

• Nasdaq delisted common stock in May 2024; now trades on OTC Pink Market under "AFIB."

• Restructuring resulted in a 65% workforce reduction and significant cost-cutting.

• Operating income for continuing operations reached $0.1M, up 119% from the prior year.

Financial highlights

• Revenue for the quarter ended September 30, 2024 was $5.3M, up 156% year-over-year; nine-month revenue was $13.0M, up 170%.

• Gross margin improved to 7% for the quarter (from -53% year-over-year); nine-month gross margin was 0% (from -63%).

• Net loss for the quarter was $5.6M, a 58% improvement year-over-year; nine-month net loss was $8.1M, down from $47.9M.

• Net loss from continuing operations for nine months was $3.2M, down from $9.9M year-over-year.

• Net cash used in operating activities (continuing operations) was $15.9M for the nine months ended September 30, 2024.

Outlook and guidance

• Management believes current cash, equivalents, and marketable securities are sufficient to fund operations for at least the next 12 months.

• No further financial guidance will be provided due to the strategic exit from electrophysiology mapping and ablation businesses and focus on left-heart access distribution.

• Future performance is highly dependent on Medtronic's sales and the ability to achieve earnouts.

• Restructuring is expected to reduce operating expenses and optimize cash resources.